SCHEMBL16748485

SCHEMBL16748485

Cc1nc2ccccc2n1-c1nc(NCCO)nc(Nc2cnc3ccccc3c2)n1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.45
MCL1 Q07820 1/20 0.45
GBA1 P04062 10/20 0.45
PIK3CD O00329 2/20 0.43
PIK3CA P42336 2/20 0.43
PIK3CB P42338 2/20 0.43
PIK3CG P48736 2/20 0.43
KCNH3 Q9ULD8 1/20 0.42
TSHR P16473 1/20 0.41
TNF P01375 1/20 0.40
BMI1 P35226 1/20 0.40
IGF1R P08069 1/20 0.40
SLC2A1 P11166 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
BRAF P15056 1/20 0.39
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740739 0.82 PIK3CA (0.47) PIK3CDPIK3CAPIK3CBPIK3CGTNF
SCHEMBL16748486 0.79 GBA1 (0.46) RECQLMCL1GBA1PIK3CDPIK3CA
SCHEMBL16748491 0.76 TERT (0.43) PIK3CABMI1IGF1RMTOR
SCHEMBL16740717 0.71 PIK3CA (0.47) PIK3CDPIK3CAPIK3CBPIK3CGTNF
Hydrochloric Acid SCHEMBL3786325 0.69 PIK3CD (0.49) GBA1PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1104835 0.68 MAPK1 (0.63) PIK3CDPIK3CAPIK3CBPIK3CGTSHR
SCHEMBL16740858 0.67 GBA1 (0.43) RECQLMCL1GBA1KCNH3BMI1
SCHEMBL16541063 0.67 BMI1 (0.61) PIK3CDPIK3CAPIK3CBPIK3CGBMI1
SCHEMBL15747601 0.67 BMI1 (0.64) PIK3CDPIK3CAPIK3CBPIK3CGTSHR
SCHEMBL24490443 0.67 TNF (0.52) RECQLTNFIGF1RTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B RECQL 3991/4885MCL1 31/4885GBA1 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.